Skip to main content

Test Price

2,800 AED

✅ Home Collection Available

CEACAM16 Gene Deafness Autosomal Dominant Type 4B Genetic Test in UAE | 2,800 AED | DHA Licensed

Executive Summary & Core Metrics

  • Diagnostic Sensitivity: 99.9% across entire gene via ISO-accredited processing
  • Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM
  • Post-Test Clinical Consultation: Telephonic interpretation with a board-certified geneticist
  • Insurance Verification: Direct billing inquiry via WhatsApp +971 54 548 8731

Test Overview & Methodology

This advanced next-generation sequencing (NGS) test identifies pathogenic variants in the CEACAM16 gene linked to autosomal dominant deafness type 4B, enabling precise clinical diagnosis and informed family planning.

Feature Our Test (CEACAM16 NGS) Closest Alternative (Single Gene Sanger Sequencing)
Precision 99.9% sensitivity, full gene coverage with CNV analysis ~95% sensitivity, limited to known hot-spots, no CNV detection
Methodology Next-Generation Sequencing (NGS) including copy number variation (CNV) detection Sanger sequencing, no CNV analysis
Turnaround Time 3–4 Weeks 4–6 Weeks
Regulatory Compliance DHA Licensed (Facility #1143), ISO 9001:2015, Premises 105, Floor 1, Building 33, Dubai Healthcare City Variable
Price 2,800 AED 3,500–4,500 AED

Physician Insight & Safety Protocols

"As a Consultant Medical Genetics, I emphasize that genetic results must be interpreted alongside a thorough audiological and family history evaluation. A CEACAM16 variant identified on NGS confirms the hereditary nature of hearing loss, but it is only one piece of a complete diagnostic puzzle. Patients should never alter any prescribed treatment regimen without first consulting their managing ENT specialist or genetic counselor." – Lina Osama Zaki Quteineh, DHA License: 9294403

Clinical Advisory

Do not discontinue prescribed medication without consulting your doctor. Genetic test results do not override current therapeutic plans. Always interpret with complete clinical context.

Exclusion Criteria & Emergency Red Flags

  • Exclusion: Individuals who have undergone allogeneic bone marrow transplant within 6 months (may compromise germline DNA accuracy).
  • Exclusion: Uncontrolled active infection that may delay blood draw or sample stability.
  • Red Flag: If the patient presents with sudden, rapidly progressive hearing loss or neurological symptoms, urgent clinical evaluation is required; do not rely on genetic testing alone.

Patient FAQ & Clinical Guidance

1. What is the purpose of CEACAM16 gene testing for hearing loss?

This test identifies inherited mutations in the CEACAM16 gene to confirm a genetic cause for autosomal dominant sensorineural hearing loss, enabling accurate prognosis and family risk assessment.

2. How is the sample collected and what preparation is needed?

A simple blood draw, extracted DNA, or a drop of blood on an FTA card is required; no fasting or medication changes are necessary before collection. VIP home phlebotomy is available daily from 8 AM to 11 PM.

3. Does the result impact health or life insurance in the UAE?

Under UAE Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, genetic data is classified as sensitive and cannot be used to deny coverage or employment without explicit consent.

UAE Regulatory & Data Privacy Adherence

We strictly adhere to the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent follow Federal Decree-Law No. 4 of 2016 on Medical Liability. All genetic data is processed confidentially and in full compliance with DHA regulations.

Clinical & Logistical Metadata

Test Name CEACAM16 Gene Deafness Autosomal Dominant Type 4B Genetic Test
Price (AED) 2,800
Turnaround Time 3–4 Weeks
Sample Type / Matrix Whole Blood (EDTA), DNA Extract, or Dried Blood Spot (FTA Card)
Methodology Used Next-Generation Sequencing (NGS) with CNV Analysis
ICD-10-CM Code H90.5
LOINC Code 55233-1
DHA Facility License & Laboratory Address Invariants License Number: 1143, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE

دعم ثنائي اللغة متاح

التحقق من التغطية التأمينية

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.

✅ DHA Certified ✅ ISO 15189 ✅ HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

🏅

ISMS 27001:2022

📋

ISO Accredited

🔒

HIPAA

All reports reviewed by DHA-Certified physicians